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Regulation of LFA-l-mediated T cell adhesion by 
CD4*
Heterotypic adhesion of T lymphocytes to monocytes, B lymphocytes, or other 
target cells is mainly mediated by LFA-1 and CD 2 molecules. Low-affinity 
binding of restingTcells can be transiently up-regulated by cross-linking of CD3. 
We have previously found that binding of specific ligands to CD4 can 
down-regulate adhesion of resting T cells to B cells. We now show that the 
enhanced adhesiveness of CD4+ T cells induced by CD3 cross-linking using 
plastic-bound anti-CD3 antibody can also be inhibited by several CD4 ligands, 
i.e. anti-CD4 antibodies, the gpl60 env protein of human immunodeficiency 
virus, as well as by putative CD4 ligands, i.e. synthetic peptides analogous to the 
gp 160-binding site to CD4 (positions 418-434 and 449-464) and a 12-mer 
synthetic peptide (DR-12) analogous to positions 35-46 of HLA class II |3 subunit 
and including the highly conserved Arg-Phe-Asp-Ser (RFDS) sequence»
After CD3 cross-linking, maximal binding of Tcells to HLA class II-positive and 
-negative B cells was similar, although binding to HLA class II-negative B cells 
was more prolonged.Tcells that were passively induced to up-regulate adhesion 
by binding of a CD 1 la-specific antibody, NKIL16, known to enhance LFA-
1-dependent adhesiveness, were less sensitive to the inhibitory effect of the 
DR-12 peptide, whereas the inhibitory effects of gpl60 were preserved. The 
kinetics of adhesion of NKIL16-pretreated T cells was not influenced by LILA 
class II expression at the B cell surface. Together, these results strongly suggest 
that CD4-HLA class II interaction may down-regulate low-affinity adhesion of 
resting T cells and, to some extent, high-affinity adhesion of T cells actively 
induced by CD3 cross-linking but not passively induced by an anti-CD 11a 
antibody
1 Introduction
The antigen-independent heterotypic adhesion of Tcells to 
monocytes, B cells or other target cells is mainly mediated 
by two independent molecular pathways, i.e. LFA-1 
(CDlla-CD18) binding to ICAM-1 (CD54) or ICAM-2 
ligands and CD2 binding to LFA-3 (LCD58; [1—3]), Such 
adhesion processes are required for T cell activation and 
effector functions. This has been demonstrated in blocking 
experiments using specific mAb [4-6] and showing altered 
binding and functions of T ceils defective in LFA-1 expres­
sion [6-8], as well as poor binding and cytotoxic function of 
T cells towards ICAM-1" LFA-3“ Burkitt B cells [9]. 
Finally, transfection of murine fibroblasts with ICAM-1 or 
LFA-3, in association with MHC molecules, leads to 
optimal binding and activation of specific T cells [10-12]. 
The LFA-1- and CD2-dependent low-affinity binding of T 
cells can be up-regulated when expression of adhesion 
molecules (LFA-1 and ICAM-1) is increased following the 
secretion of IL 1, IFN-y and TNF [3, 13]. This event is 
secondary to T cell activation and can thus not account for 
mediating early T cell adhesion associated with T cell 
activation [1, 2]. Recently, Dustin and Springer [14] and
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Keizer et al. [15] demonstrated that CD3 cross-linking may 
result in an early up-regulation of Tcell adhesion that relies 
on a transient increase in the affinity of LFA-1 for its ligand 
[16, 17]. This event is thought to be mediated by a 
conformational change related to PKC phosphorylation of 
LFA-1 or of an associated protein [14, 17]. A more 
prolonged up-regulation of T cell adhesion can also be 
induced by an LFA-1-specific antibody, NKIL16, that may 
induce homotypic cell agregation [15].
We have previously provided experimental evidence sup­
porting the hypothesis that the CD4-MHC class II interac­
tion could down-regulate the low-affinity binding of resting 
CD4+ T cells to B cells ([6], Mazerolles et al., Hum. 
I m m u n o l in press). Indeed, resting CD4+ T cells show 
similar maximal binding to MHC class II-positive and 
-negative B cells, although binding to class I I+ B cells is 
transient whereas binding to class II“ B cells is prolonged 
for at least 20 min. Finally, anti-CD4 antibodies and the 
gpl60 envelope protein from HIV (which binds to CD4; 
Coradoet al., submitted), as well as peptides encompassing 
the gp 160-binding site to CD4 [18] and peptides analogous 
to the 35-46 sequence of MHC class II (3 chains and 
containing the highly preserved RFDS sequence [19], all 
inhibit CD4'h T cell-B cell adhesion. This suggests that 
CD4-MHC class II interaction, possibly mediated in part by 
the MHC class II RFDS sequence, and gpl60 binding to 
CD4, can down-regulate antigen-independent adhesion of 
CD4+ Tcells.
In this study, we have determined whether CD4 is involved 
in the regulation of the high-affinity binding of CD4+ Tcells 
previously induced by CD3 cross-linking or NKIL16 (anti- 
CD 11a) antibody binding.
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2 Materials and methods
2,1 Antibodies and peptides
The following mAb were used in the adhesion assays:
NKIL16 (IgG2a, anti-CD 11a LFA-1, culture SN [15]), 25.3 
(IgGi, anti-CD 11a, LFA-1, D. Olive, Marseille, France; 
[20]), TS1.18 (IgGi, anti-LFA-1 P subunit [CD 18], T. 
Springer, Boston, MA; [21], OKT3, OKT4a (IgG2a, anti- 
CD3, anti-CD4, respectively, Orthodiagnostic, Raritan, 
NJ), 84H10 (IgGi, anti-ICAM-1 (CD54); D. Olive; [22], 
BC18 (IgG2a, anti-CD2, C. Anasetti, Seattle, WA), IOT8 
(IgGi, anti-CD8, Immunotech, Marseille, France), ALB9, 
IOT7 (IgGi, IgG2a, anti-CD24, anti-CD7 respectively, 
Immunotech), Leu-1 (IgG2a, anti-CD5, Becton Dickinson, 
Mountain View, CA),
DR-12 peptide (EEYVRFDSDVGE) is analogous to resi­
dues 35 to 46 from the Pi domain of HLA-DR1.2 [19]. 
DR43-54 peptide (DVGEYRAVTELG) is analogous to 
residues 43 to 54 from the pi domain of HLA DR1.2 class I 
31-42 peptide (TQFVRFDSDAAS) is analogous to resi­
dues 31 to 42 from the a* domain of HLA class IA2. DR12 
variant peptides were also used, i.e. DR12 VI (EEYVR- 
DSDVGE), DR12 V2 (EEYRGDSDVGE), DR12 V4 
(EEYRFESDVGE). All were synthesized by Neosystem 
(Strasbourg, France) according to the solid-phase synthesis 
method of Merrifield, and further purified by HPLC, 
resulting in >96% purity, as shown by HPLC analysis. 
Peptide sequences were validated by amino acid analysis of 
the purified preparations.
The gpl60 (env; M. Kaczorek, Pasteur-Vaccins, Val de 
Reuil, France), was secreted by BHK-21 cells after infection 
with a recombinant vaccinia vims (W-1163) expressing a 
complete env glycoprotein from the HIV-1 BRU isolate 
[23] and purified (Pasteur-Vaccins) from the culture SN by 
means of DEAE ion-exchange chromatography, lectin 
affinity chromatography and gel filtration chromatography, 
under sterile conditions. Purity was at least 90% as 
determined by reverse-phase HPLC and Western blot 
analysis. Peptides : 302-324 (TRPNNNTRKSIR1QRGP- 
GRAFVT), 418-434 (STEGSNNTEGSDTITLP), 
449-464 (KAKYAPPISGQIRCSS) derived from the gpl60 
sequence of the HIV-1 BRU isolate were synthesized by 
Neosystem using the solid-phase synthesis method of 
Merrifield and further purified (to > 85% purity) using 
HPLC Peptides sequences were validated by amino acid 
analysis of the purified preparations.The soluble CD4 given 
by Dr. A. Truneh (Smith Kline and French Laboratory, 
Swedeland, PA) was obtained by recombinant DNA tech- 
nology.This soluble CD4 retains the structural and biolog­
ical properties of CD4 on the cell surface.
2.2 Cell preparations
PBMC from healthy adults were isolated using Ficoll 
Hypaque (Pharmacia, Uppsala, Sweden) centrifugation. 
CD4+ T lymphocytes were isolated from PBMC by a 
two-step procedure, Le. neuraminidase-treated RBC reset­
ting, followed by negative selection by panning using a 
CD8-specific mAb (13 CS, J.W.Wijdenes, Besançon, France; 
L5 {¿g/106 cells) and an goat anti-mouse Ig antibody 
(GaMlgG, Biomaker, Rehovot, Israel). CD4+, T cell
preparations contained < 2% CD8+ T cells. CD4+ T cells 
were also purified from PBMC of a patient with leukocyte 
adhesion deficiency (LAD) and very low leukocyte expres- 
.sion of LFA-1 [5]. EBV-induced B cell lines were prepared 
from PBMC of healthy individuals and from immunodefi- 
cient patients with an inherited deficiency in HLA class II 
expression molecules [24]. Mutant HLA class I I '  B cells 
(RJ225) produced by Accolla et al. [25] were cultured as 
described. In some experiments, CD4+ T lymphocytes 
were preincubated with NKIL16 at 37 °C for 15 min, then 
washed and incubated with EBV-B cell lines for conjugate 
formation.
CD4+ T lymphocytes were also activated by anti-CD3 
antibody (OKT3), according to the method of Dustin and 
Springer [14] with slight modifications. Briefly, CD4+ Tee 11 
(107/ml) were incubated in 5% FCS for 30 min at 4°C on 
petri dishes precoated with OKT3 (50 pig/ml) for 1 h at 
37 °C. Unbound cells were eliminated by washing; bound 
cells were removed using a rubber policeman, washed and 
used for conjugate formation.
2.3 Immunofluorescence
Cell fluorescence intensity was evaluated by means of FCM 
analysis using a FACS tar plus (Becton Dickinson) following 
revelation by specific antibodies and by a GaMlg (Nordic, 
Tilburg, The Netherlands).
2.4 Conjugate formation
Antigen-independent T-B conjugate formation was 
induced according to the method described by Onishi et al. 
[26]. Briefly, T and B cells (both at 2 x 10rYml) were 
incubated with hydroethydine (40 ng/ml, Polysciences, 
Warrington, PA) for 10 min at 25 °C and fluorescein 
diacetate sulfate (100 i^g/ml, Molecular Probes Inc, 
Eugene, OR) for 10 min at 37°C. After washing, 5 X  105 
resting or activated Tcells were mixed with 5 x 105 B cells in 
a 500 \d volume of RPMI 1640 medium (Gibco Biocult, 
Paisley, Scotland). Preliminary experiments showed that 
optimal conjugate formation took place after 20 min of 
incubation at 37 °C. Incubation was followed by centrifuga­
tion at 250 x g for 5 min and gentle resuspension before 
counting, Conjugates were identified as red/green pairs of 
cells under fluorescence microscopy. Fluorescent cells 
(250-350) were counted blind in each experiment. Exper­
iments performed in duplicate by independant observers 
were not significantly different. Results are expressed as the 
percentage of T-B conjugates relative to total Tcells or as 
the inhibition of T-B conjugate formation : [1 -  (TB/T : TB 
control / T  control)] X  100. Statistical analysis was per­
formed by using the Student’s ¿-test.
3 Results
3.1 Up-regulation of CD4+ T cell adhesion by anti-CD3 
(OKT3) and anti-LFA-1 (NKIL16) antibodies
As shown in Fig. 1A, incubation of resting CD4+ T 
lymphocytes with increasing concentrations of plastic-
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Figure 1. Up-regulation of CD4+ 
T cell adhesion by anti-CD3 and 
NKIL16 antibodies. Resting CD4+ 
T cells were preactivated with var­
ious concentrations of anti-CD3 
antibody : OKT3 (A) or anti-LFA-
1 (CD lla) : NKIL16 antibody (B) 
as described in Sect. 2,2, then 
washed and incubated with EBV-B 
cell lines for conjugate formation. 
In (C) and (D), kinetics of anti- 
CD3 (50 (xg/ml) and NKIL16 (1/50 
culture SN)-activated CD4+ T cell 
adhesion to EBV-B cells. Results 
are the mean of seven independent 
experiments ±  1 SD,
bound OKT3 antibody resulted in a significant increase in 
the percentage of T cells able to bind EBV-transformecl B 
cells. Differences were significant with concentrations of 
OKT3 antibody >  0.2 (p <  0.01). As for resting CD4+ T 
cells, peak of conjugate formation was still observed after a
20 min incubation (Figs. 1C and 2 A). Interestingly, CD4+ 
Tcells that were activated by CD3 cross-linking were found 
to adhere only transiently to B cells, since the percentage of 
conjugates dropped off rapidly after 20 min.
NKIL16 is a CD 1 la-specific antibody, known to enhance 
homotypicTcell adhesion and agrégation [15]. Our results 
indicate that a short incubation of CD4+ T cells with 
increasing concentrations of NKIL16 (Fig. IB ) induces 
up-regulation of adhesion to B cells; peak conjugate 
formation occurred after 20 min of incubation, with a 
plateau until 45 min, after which a decrease was observed in 
the presence of NKIL16 antibody concentrations >  50 X 
10~[ (Figs. ID  and 2 A).
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Figure 2. LFA-ldependency of anti-CD3- and NKIL16-induced up-regulation of Tcell adhesion. (A) Kinetics of adhesion of resting (+ ) ,  
OKT3~activated (□) and of NKIL16-activated (O) CD4+Tcells to B cells. (B) Kinetics of adhesion of resting ( ♦ )  and OKT3-preactivated 
LFA-1-deficient CD4' Tcells (□) to B cells. (C) Kinetics of adhesion of resting (+ )  and NKIL16-preactivated LFA-1-deficient CD4+ T 
cells (O) to B cells. The results of one typical experiment (mean ± SD of duplicates) among five experiments are shown.
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Figure 3. Inhibition of anti-
CD 3- and NKIL16-induced up- 
regulation of T cell adhesion. 
CD4+ T cells preactivated with 
OKT3 at 50 i^g/ml (A) or NKIL16 
at 1/50 dilution (B), as described 
in Fig. l,were mixed with EBV-B
cell lines in the presence of the 
antibodies indicated (20 min, 
37°C) for conjugate formation. 
Anti-CDlla, -CD 18, -CD54, 
-CD2 (CD2a : BC18; CD2b : 
OKT11), antibodies (1 pig/ml). 
Anti-CD5, -CD8, -CD7, -CD24 
antibodies (10 ftg/ml). The per­
centage of control T-B conjugates 
was, in (A): resting CD4+ Tcells:
13 ± 2 .5%, preactivated CD4+ Tcells: 20 ±  2%; in (B): resting CD4+ Tcells: 10.5 ± 2%; preactivated CD4+ Tcells: 20.3 ± 2%,The 
results of one typical experiment (mean ± SD of duplicates) among five experiments are shown.
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It has been found that anti-CD3-induced up-regulation of T 
cell adhesion is an LFA~ 1-dependent phenomenon, as is the 
case for binding of T cells to purified ICAM-1 molecules 
[14], that is, however, independent of the degree of 
membrane expression of LFA-1 [14].This was confirmed in 
our CD4+ T-B conjugate formation assay, since no up- 
regulation of adhesion of CD 11a-  T cells from patients 
LAD was observed (Fig. 2B). In addition, anti-LFA-1 
(CDlla and CD18) and anti-ICAM-1 antibodies strongly 
inhibited anti-CD3-activated CD4^ T cell adhesion (Fig. 
3 a). However, anti-CD2 antibodies were still able to inhibit 
adhesion of the sameTcells, indicating that CD2 partici­
pates in the adhesion of anti-CD3-activated Tcells.
As expected, the NKIL16-induced up-regulation of CD44* 
T cell adhesion was also found to be dependent on LFA-1 
expression (Fig. 2C). Such adhesion was, however, also 
CD2 dependent, as shown by the partial blocking effect of 
anti-CD2 antibodies (Fig. 3B). Isotype-matched (IgGv or 
IgG2a) anti-CDS, CD7, CD8 and CD24 antibodies had no 
effect on either type of activated Tcell adhesion to B cells
(Fig. 3).
3.2 Inhibition of anti-CD3- and NKIL16-activated CD4+ 
T cell adhesion by anti-CD4 antibody, MHC class
II-derived peptides, gpl60 and gpl60-derived 
peptides
To assess whether the CD4 molecule is involved in the 
adhesion of T cells preincubated with either anti-CD3 or 
NKL16 antibodies, we investigated the potential inhibitory 
activity of CD4 ligands (anti-CD4 antibody and gpl60), as 
well as putative CD4 ligands (an MHC class II-derived 
peptide mimicking the 35-46 sequence of (31 and gpl60- 
derived peptides). All these reagents have previously been 
shown to specifically inhibit adhesion of resting CD4+ T 
cells ([6]; Corado et al; submitted). Initially it was checked 
that Tcell incubation with anti-CD3 or NKIL16 antibodies 
did not significantly alter CD4 expression compared to 
resting cells (data not shown).
As shown in Fig. 4, the anti-CD4 antibody OKT4a was able 
to inhibit both anti-CD3 and NKIL16 activated T cell 
adhesion and adhesion of resting CD4+ T cells [6], In 
addition, this antibody was equally effective on the adhe-
t tig/ml
(H) (b)
Figure 4. Inhibition by anti- 
CD4 antibody (OKT4A) of the 
CD4+ T cell adhesion to MHC 
class II+ and MHC class II“ B 
cells. (A): Adhesion to MHC 
class II+ B cells. (B): Adhesion 
to MHC class II“ B cells. CD4+ 
T cells were either resting (E3), 
activated by OKT3 (50 jig/ml; 
plastic-bound; (83) or NKIL16 
(final dilution 1:50 culture SN;
). The percentages of control 
T-B conjugates were: for rest­
ing CD4+ Tcells: 12 ±  2%, for anti-CD3-preactivated CD4+ Tcells: 21 ±  2% and for NKIL16-preactivated CD4+ T: 24 ± 3.The results of 
one typical experiment (mean ±  SD of duplicates) among five experiments are shown.
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Figure 5. Inhibition of anti- 
CD3- and NKIL16-activated 
CD4+ T cell adhesion by gpl60 
and by MHCS class II-derived 
peptides. gpl60 (A), and DR-12 
peptide (B) were incubated with 
resting (A), OKT3-preactivated 
( • ) ,  or NKIL16-preactivated 
(O) CD4+ T cells during conju­
gate formation with HLA class 
II+ B cells. The percentages of 
control T-B conjugates were: for 
resting T cells: 11 ± 1%, for 
OKT3-preactivated Tcells: 21 ± 
2%, for NKIL16-preactivated T
ceils: 26 ± 3%. Peptide DR43-54
and class 1 31-42 had an inhibitory activity of <  1% on OKT3-treated Tcell adhesion and of <  3% on NKIL16-treated Tcell adhesion 
respectively. The results of one typical experiment (mean ± SD of duplicates) among six experiments are shown.
TTTT 1 I ITT 1 v i«« r |
1 10
gp)6D CONCENTRATION (rtM)
100 1000 0.1 1 10 
DR 12 CONCENTRATION (^M)
100
sion of CD4+ T cells to MHC class I I '  (Fig. 4B) and MFIC 
class II+ B cells (Fig. 4 a). Purified gpl60 similarly inhibited 
the adhesion of resting and anti-CD3- and NKIL16- 
activated CD4+ T cells (Fig. 5 A). The DR-12 peptide 
analogous to position 35 to 46 of MHC class II (3 was 
significantly more active in inhibiting the adhesion of 
resting CD4+ Tcells than that of anti-CD3-activated Tcells 
{p <  0.0001). The NKlL16-activated CD4+ Tcell adhesion 
was less sensitive to DR-12-mediated inhibition for DR-12 
concentrations below 10 \M  (Fig. 5B; p <  0.001). Control
12-mer peptides (class I 31-42, DR 43-54) and DR12 
variants (DR12 VI, DR12 V2, DR12 V4) had no effect. 
Further evidence of specificity of the inhibition by DR12 
was also provided by preincubation of this peptide with 
soluble CD4 that led to neutralization of the inhibitory
effect of DR12 (Fig. 6). It is noteworthy that neutralization 
by soluble CD4 of the DR12 peptide inhibitory effect was 
not equimolar, suggesting that not all peptides had the 
optimal conformation, as already observed in previous 
experiments [6], Finally, two gp 160-derived peptides ana­
logous to positions 418-434 and 449-464, respectively, 
known to participate to the binding of gpl60 to CD4 [18] 
were more potent in suppressing the adhesion of resting 
CD4+ Tcells than that of anti-CD3- or NKlL16-activated T 
cells (Fig. 7; p  <0.001 and p  <0,0001, respectively, for 
concentrations of 0.4 pM and 4 jam). However, identical 
maximal inhibition of adhesion could be reached with the 
two peptides. A control peptide (302-324) derived from 
gpl60 had no effect.
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Figure 6. Specific inhibition of anti-CD3- and NKIL16-activated 
CD4+ Tcell adhesion by DR-12 (35-46). DR-12 (35-46) and DR-12 
(35-46) variants peptides were incubated (at 12 (iM with NKIL16- 
preactivated CD4+) T cells in (A) or OKT3-DR-12 (35-46; 12 |aM) 
was^  preincubated with soluble CD4 (at 200 nM) during 10 min at
37 °C before incubation with Tand B cells for conjugate formation. 
The percentages of control T-B conjugastes were: (A): 23 ± 2% 
and (B): 19 ± 2% .The results of one typical experiment (mean ± 
SD of duplicates) among five experiments are shown.
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Figure 7.  Inhibition of anti-CD3- and of NKIL16«activated CD4+ 
T cells by gpl60-derived peptides. Resting (H) NKIL16-preacti- 
vated (^ )  or OKT3-preactivated (E&) CD4+ Tcells were incubated 
during conjugate formation with HLA class II* B cells with 
gpl6G-derived peptides (418-434, 449-464, 302-324).The percen­
tages of control T-B conjugates were: for restingTcells: 9 ±  2%, for 
NKIL16-preactivated Tcells: 21 ± 2% and for OKT3-preactivated 
Tcells: 21 ±  2% .The results of one typical experiment (mean ± SD 
of duplicates) among four experiments are shown.
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(B) Figure 8. Kinetics of adhesion 
of anti-CD3- and NKI-L16 acti­
vated CD4+ T cells to MHC 
class II+ and MHC class II“ B 
cell lines. (A): HLA class I I1 B 
cells were incubated with rest­
ing (A) or OKT3-preactivated 
CD4+ T cells (A). HLA c lass 
I r  B cells (RJ225) were incu­
bated with resting (O) or 
OKT3-preactivated CD4+ T 
cells ( • ) .  (B): HLA class II+ B 
cells were incubated with rest­
ing (A) or NKIL16-activated 
CD4+ T cells (A). HLA class 
II- B cells were incubated with 
resting (O) or NKIL16-acti- 
vated CD4+Tcells ( • ) .  Results
are the mean of six experiments ± 1 SD, Similar results were obtained by using an EBV-B cell line from an immunodeficient patient with 
defective expression of HLA class II molecules ([24]; data not shown).
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3.3 Kinetics of adhesion of anti-CD3-activated CD4+ T 
cells to MHC class II+ and MHC class II" B cell 
lines
As we have previously shown [6], the kinetics of adhesion of 
resting CD4+ Tcells to MHC class II* and MHC class II ~ B 
cells differed strongly (Fig. 8): Adhesion to class II“ B cells 
is prolonged, remaining at a plateau for 20 to 40 mm, 
whereas adhesion to class II+ B cells peaks and then drops 
off rapidly. It has been suggested that this MHC class
II-Telated alteration of adhesion reflects a negative regula­
tion of T cell adhesion mediated by weak interactions 
between CD4 and MHC class II molecules [6]. We, 
therefore, tested whether such regulation was active in 
anti-CD3-activated CD4+ Tcells. As shown in Fig. 8 a, we 
found almost identical maximal binding of anti-CD3- 
activated CD4+ Tcells to MHC class II+ and MHC class II” 
B cells.This was shown using both mutant RJ225 B cells and 
B cells from patients with defective MHC class II expres­
sion; these B cells express similar levels of the adhesion 
molecules ICAM-1 and LFA-3 (data not shown). The 
kinetics of adhesion of anti-CD3-activated CD4'K T cell to 
MHC class II“ B cells did not follow a plateau similar to that 
of resting CD4+ T cells. The slope of the decrease in T-B 
conjugates between 20 and 60 min was, however, signifi­
cantly shallower than that observed with MHC class 11+ B 
cells (Fig. 8a; p  <0.01). NKIL16-activated Tcells bound 
MHC class II+ and MHC class H~ B cells to the same 
extent, with a moderate decrease in conjugates formation 
after 40 min (Fig. 8 b).
4 Discussion
In this work, we studied the adhesion of CD4+ T cells that 
had been activated either by CD3 cross-linking or by the 
CDlla-sepcific antibody NKIL16. We confirm that in both 
instances, the observed up-regulation of adhesion, com­
pared to resting cells is LFA-1 dependent. In addition, CD2 
was again found to be involved in the adhesion pathway 
This up-regulated adhesion was inhibited by anti-CD4 
antibodies and gpl60 and was partially inhibited by gpl60- 
derived peptides. The adhesion of anti-CD3 antibody- 
activated CD4+ T cells was also partially inhibited by the
DR-12 peptide which mimicks the 35-46 sequence of MHC 
class II ¡3 molecules whereas the adhesion of NKIL16- 
activated CD4+ T cells was only slightly inhibited. In 
addition, anti-CD3 antibody- and NKIL16-activated CD4+ 
T cells bound equally to B cells regardless of MHC class II 
expression. The drop of adhesion of CD3-cross-linked 
CD4+ T cells to MHC class II+ B cells after a 20 min 
incubation was more pronounced than that observed with 
class II- B cells.
These results can be interpreted in several ways. The CD4 
molecule could be involved as an adhesion molecule in 
CD3- or LFA-l-preactivated CD4+ Tcell adhesion. This is 
supported by the significant role of CD4 in antigen-specific 
T cell adhesion [27, 28]. Similarly, it has been recently 
shown that in a long-term (1 to 2,5 h) adhesion assay TcR 
triggering could up-regulate the CD8-MHC class I interac­
tion [29]. However, it has been found that CD4 has no 
detectable role in mediating antigen-independent adhesion 
of resting or clonal CD4+ Tcell populations [6, 26]. In the 
system we studied no difference in the adhesion of activated 
CD4+ Tcells to MHC class II+ and MHC class II ‘ B cells 
was detected. This distinguishes these models from MHC 
class II-restricted binding of T cells to murine fibroblasts 
transfected with human MHC class II molecules [11], where 
a TcR-MHC class II molecule interaction mediates adhe­
sion.
These results do not rule out the hypothesis that CD4 is 
involved in the up-regulation of adhesion induced by CD3 
cross-linking, since CD4-CD3 association is known to occur 
in T cell activation [30, 31] and could facilitate signal 
transduction leading to up-regulation of adhesion [14, 32]. 
This question could be only addressed by testing inhibition 
of adhesion by the addition of CD4 ligands at the time of 
CD3 cross-linking or by studying the effect of CD3 
cross-linking on CD4“CD3+ T cells.
CD4 ligands could inhibit up-regulation of adhesion by 
inducing dissociation of a CD3/TcR/CD4 complex. This 
explanation could account for the inhibition of CD3- 
mediated up-regulation of T cell adhesion but not that of 
LFA-l-mediated up-regulation. The latter is known not to 
depend upon a CD4-CD3/TcR interaction [15].
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The present results are, thus, compatible with the hypo­
thesis that CD4 ligands and putative CD4 ligands (gpl60 
and MHC class II-derived peptides) can inhibit through 
negative signaling of both activated and resting T cell 
adhesion ([6,33,34]; Mazerolles et aL, Hum. Immunol., in 
press). Indeed, having made similar observations in the 
study of the adhesion of resting CD4+ Tcells, we proposed 
that CD4 can transduce a signal negatively regulating cell 
adhesion after ligand binding ([6]; Corado et a l , submitted 
and Mazerolles et al., Hum. Immunol., in press). CD4- 
CD4 ligand interaction would exert negative effects onTcell 
adhesion and possibly T cell activation [35, 36] when the 
CD4 ligand does not cross-link CD4 and the TcR/CD3 
complex; this would contrast with the antigenic peptide- 
MHC class II complex which induces a positive signal [30, 
31]. A similar mechanism could also control the adhesion of 
CD3-cross-linked T cells and of LFA-l-stimulated Tcells. 
CD4 cross-linking would not be required as proposed by 
Hague et al. [37], since gpl60 was found to be effective.
However, putative CD4 ligands (gp 160-derived peptides 
that mimick the gpl60 binding site to CD4 [18] and the 
DR-12 peptide analogous to the 35-46 sequence of HLA 
class II (3, including the highly preserved RFDS sequence) 
that specifically inhibit adhesion of resting CD4+ Tcells to 
B cells were less active on T cells preactivated by CD3 
cross-linking. These results, differing from those observed 
with resting CD4+ Tcells, may be explained by the higher 
affinity of LFA-l-mediated interactions [17]. It is likely that 
peptides are less active on T cells that display a higher 
affinity for their targets. Indeed, Dustin and Springer 
demonstrated that the anti-CD3-induced up-regulation of 
adhesion relies on an increased affinity of LFA-1 for its 
ligand since LFA-1-dependent up-regulation of adhesion 
was not associated with a rise in the number of membrane 
LFA-1 molecules [14,16].They also demonstrated that this 
up-regulation was an active and transient phenomenon. In 
addition, the adhesion of such Tcells to purified ICAM-1 
was also transient,This indicates that negative regulation of 
this process results in part from cessation of the positive 
signaling induced by CD3 cross-linking which may be 
mediated by PKC activation and phosphorylation of either 
LFA-1, or of an associated molecule [14,16].This was also 
found in our experimental model since down-regulation of 
anti-CD3-activated Tcell adhesion was also observed in the 
absence of CD4-MHC class II interaction by studying 
adhesion to MHC class II" B cells* Here, we demonstrate 
that the CD3-dependent up-regulation of LFA-l-depen- 
dent adhesion can also be down-regulated by CD4-CD4 
ligand interaction. Indeed CD3-activated CD4+ Tcells bind 
in a more prolonged manner to MHC class II” B cells than 
to  MHC class 11+ B cells; furthermore, CD4 ligands 
partially inhibited the CD3-mediated up-regulation of T 
cell adhesion and anti-CD4 antibodies inhibit the interac­
tion of anti-CD3 antibody-activated CD4+ T cells with 
MHC class II” B cells. This effect is not secondary to a 
CD4-induced LFA-1 modulation since LFA-1 expression is 
not modified in the presence of CD4 ligands ([6]; Corado et 
al., submitted).
A s previously demonstrated by Keizer et al. [15] for 
homotypic adhesion, the NKIL16-mediated up-regulation 
o f  Tcell adhesion to B cells is relatively stable. No influence 
o f  potential CD4-MHC class II interaction on the kinetics 
o f  T-B cell adhesion was found. In addition, putative CD4
ligands had moderate inhibitory activities on the adhesion 
of NKIL16-treated CD4'1' Tcells.The NKIL16 antibody is 
thought to increase the affinity of LFA-1 for its ligand, 
ICAM-1, by passively inducing a conformational change in 
the LFA-1 molecule [15]. It is, therefore, not surprising that 
the CD4-MHC class II interaction is far less involved in the 
regulation of such LFA-l-mediated T cell adhesion. The 
gpl60 is in contrast similarly able to inhibit adhesion of 
resting, anti-CD3- and NKIL16-pretreated Tcells, suggest­
ing that its effect either is more potent or relies on a 
different mechanism. The former hypothesis is more likely 
since the affinity of gpl60 for CD4 is much higher than that 
of MHC class II for CD4 [18].
Taken together, our results suggest that in addition to 
down-regulating low-affinity antigen-independent T ceil 
adhesion, the CD4-MHC class II interaction may also 
partially down-regulate high-affinity T cell adhesion 
induced by CD3 cross-linking. It is tempting to speculate 
that in vivo, this molecular interaction may prevent anti- 
gen-independent Tcell adhesion and may also contribute to 
terminating antigen-specificTcell adhesion up-regulated by 
CD37TcR cross-linking. This should imply either CD4- 
CD3/TcR dissociation or modulation of the CD4-CD3/TcR 
complexes formed during T cell activation, sparing CD4 
molecules not associated with the CD3/TcR complex and 
able to transduce a signal down-regulating Tcell adhesion. 
The mechanism of this signal is at present unknown, but 
may involve the p56Ick tyrosine kinase that is associated 
with CD4 [38].
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